



Integrative Metabolomic Biomarkers for Neurodegeneration

Guest Editor:

Dr. Robert Logan

Department of Biology, Eastern
Nazarene College, Quincy, MA,
USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

The biomarkers of neurodegeneration have played an increasingly important role in predicting the disease risk, establishing a diagnosis, predicting the treatment response, monitoring the disease progression, serving as drug targets, and enabling prognosis determination. Furthermore, the discovery of new biomarkers can shed light on the physiological mechanisms of neurodegeneration. The search for neurodegenerative biomarkers is actively ongoing. It is hoped that easily clinically assessable biomarkers will facilitate the earlier diagnosis of neurodegeneration, leading to improved therapies.

The connection between biomarkers and biological phenomena is strengthened when integrated with multi-omics data. Furthermore, the introduction of machine learning to integrative multi-omics data has helped to uncover novel biomarkers for disease.

The possible topics of this Special Issue include the use of integrative metabolomics to discover novel metabolite biomarkers, to describe new insights into current metabolic biomarkers, to propose novel approaches for improving the quality of data and integration of metabolomics, and to leverage metabolomic biomarkers as drug targets.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy
2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry and Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us

Metabolites Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/metabolites
metabolites@mdpi.com
[X@MetabolitesMDPI](https://twitter.com/MetabolitesMDPI)